TY  - GEN
AU  - Charles,Pierre
AU  - Terrier,Benjamin
AU  - Perrodeau,Élodie
AU  - Cohen,Pascal
AU  - Faguer,Stanislas
AU  - Huart,Antoine
AU  - Hamidou,Mohamed
AU  - Agard,Christian
AU  - Bonnotte,Bernard
AU  - Samson,Maxime
AU  - Karras,Alexandre
AU  - Jourde-Chiche,Noémie
AU  - Lifermann,François
AU  - Gobert,Pierre
AU  - Hanrotel-Saliou,Catherine
AU  - Godmer,Pascal
AU  - Martin-Silva,Nicolas
AU  - Pugnet,Grégory
AU  - Matignon,Marie
AU  - Aumaitre,Olivier
AU  - Viallard,Jean-François
AU  - Maurier,François
AU  - Meaux-Ruault,Nadine
AU  - Rivière,Sophie
AU  - Sibilia,Jean
AU  - Puéchal,Xavier
AU  - Ravaud,Philippe
AU  - Mouthon,Luc
AU  - Guillevin,Loïc
TI  - Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)
SN  - 1468-2060
PY  - 2019///0805
KW  - Adult
KW  - Aged
KW  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
KW  - drug therapy
KW  - Antibodies, Antineutrophil Cytoplasmic
KW  - blood
KW  - Antirheumatic Agents
KW  - administration & dosage
KW  - B-Lymphocyte Subsets
KW  - drug effects
KW  - Biomarkers
KW  - Drug Administration Schedule
KW  - Drug Monitoring
KW  - methods
KW  - Female
KW  - Humans
KW  - Infusions, Intravenous
KW  - Kaplan-Meier Estimate
KW  - Lymphocyte Count
KW  - Male
KW  - Middle Aged
KW  - Precision Medicine
KW  - Recurrence
KW  - Remission Induction
KW  - Rituximab
KW  - Severity of Illness Index
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1136/annrheumdis-2017-212878
ER  -